Blood and Blood Components Market Report

Global Blood and Blood Components Market Size

The global blood and blood components market size was valued at USD 36.46 billion in 2024 and is estimated to reach USD 58.73 billion by 2033 from USD 38.44 billion in 2025, registering a CAGR of 5.44% from 2025 to 2033.

Blood and blood components are a whole blood and its medically isolated fractions including red blood cells platelets plasma and cryoprecipitate. In India, for instance the National Blood Transfusion Council estimates an annual requirement of twelve million units but collects only around eleven million with regional shortages exceeding twenty five % in rural states. Blood components are not interchangeable commodities their efficacy and safety depend on donor screening cold chain integrity blood group compatibility and timely administration making this market uniquely dependent on public health infrastructure ethics and logistics rather than conventional supply demand economics.

MARKET DRIVERS

Rising Prevalence of Hematologic and Oncologic Disorders

The global escalation in hematologic malignancies and inherited blood disorders is propelling the growth of Blood and Blood Components Market. According to the International Agency for Research on Cancer, new cases of leukemia lymphoma and myeloma surpassed one point four million globally in 2023 with Asia Pacific accounting for over forty five % of incidence due to population density and aging. Thailand’s Ministry of Public Health reported a thirty two % increase in thalassemia related transfusions between 2019 and 2023 as screening programs expanded.

Expansion of Trauma and Surgical Infrastructure in Emerging Economies

The proliferation of tertiary care hospitals and trauma centers is significantly elevating the consumption of red blood cells and fresh frozen plasma for perioperative and emergency resuscitation, which is enhancing the growth of Blood and Blood Components Market. India’s National Health Mission established two hundred and seventeen new trauma care centers between 2020 and 2023 each requiring a minimum of fifteen hundred units of red cells annually as per Ministry of Health operational guidelines. Elective surgeries are also contributing with the Brazilian Society of Surgery documenting a twenty two % growth in oncologic resections in 2023 each requiring an average of three packed red cell units. This infrastructure led expansion is transforming blood from an episodic resource to a core component of national surgical readiness.

MARKET RESTRAINTS

Persistent Shortages in Voluntary Blood Donation Rates

The insufficient voluntary donor participation in regions with high disease burden is majorly hampering the growth of Blood and Blood Components Market. According to the World Health Organization less than thirty five % of low income countries collect blood exclusively from voluntary non remunerated donors increasing risks of transfusion transmitted infections and supply instability. Mobile blood drives face resistance in rural India where superstitions about blood loss persist despite government awareness campaigns.

Regulatory Fragmentation and Cold Chain Vulnerabilities

The national regulatory frameworks that impede cross border harmonization and elevate operational risk in temperature sensitive logistics, which is impeding the growth of Blood and Blood Components Market. As per India’s Drug Controller General, reported that 21% of blood banks failed cold chain compliance audits in 2023 risking degradation of platelets and coagulation factors. A study published in Transfusion Medicine by researchers at Mahidol University, 33% of Thai provincial hospitals experienced at least one cold chain breach per quarter. These systemic gaps not only compromise product efficacy but also deter investment in regional blood processing hubs.

MARKET OPPORTUNITIES

Advent of Pathogen Reduced Platelet and Plasma Technologies

The integration of pathogen reduction technologies for platelets and plasma for inventory safety extension and donor pool expansion in regions with high infectious disease prevalence, which is greatly influencing the growth of Blood and Blood Components Market. South Africa’s National Institute for Communicable Diseases, pathogen reduced platelets demonstrated a 40% longer shelf life allowing redistribution from urban collection centers to rural hospitals.

Emergence of Regional Blood Fractionation Hubs in Asia and Africa

The strategic investments in regional plasma fractionation facilities are reducing dependency on imported clotting factors and immunoglobulins while creating economic value from domestic blood collection. Fractionation not only adds value to collected plasma but also incentivizes donation through assured utilization.

MARKET CHALLENGES

Donor Demographic Imbalance in Aging Societies

The populations the donor to recipient ratio is deteriorating creating structural deficits that cannot be resolved by efficiency gains alone. According to Japan’s Red Cross Society donors aged sixty and above accounted for only three % of collections in 2023 while recipients in that age group consumed over fifty eight % of all red blood cells transfused.

Ethical and Religious Barriers to Universal Donation Access

Cultural and religious beliefs continue to impose non-clinical constraints on donor recruitment and component utilization are also to limit the growth of blood and blood components market. Jehovah’s Witness communities globally refuse transfusion of red cells and whole blood affecting clinical decision making in trauma with alternative strategies such as cell salvage and erythropoietin increasing procedural cost and complexity as noted in a 2023 review by the Journal of Medical Ethics. In India caste based misconceptions about blood purity deter inter caste donations despite identical ABO compatibility.

REPORT COVERAGE

REGIONAL ANALYSIS

By Product Insights

The plasma derived products segment was the largest and held 42.3% of the blood and blood components market due to the rising global demand for immunoglobulins, albumin, and clotting factors used in treating chronic and rare diseases such as hemophilia, primary immunodeficiency disorders, and autoimmune conditions. Regulatory approvals for new indications and the expansion of plasma fractionation capacity in emerging markets are additional growth catalysts.

The platelets segment is projected to grow at the CAGR of 8.7% during the forecast period with the rising incidence of cancer, particularly hematological malignancies like leukemia and lymphoma, which require frequent platelet transfusions during chemotherapy induced thrombocytopenia. Advancements in apheresis technology have improved donor yield and product purity, which is reducing contamination risks and extending shelf life. The emergence of pathogen reduced platelet products, approved by the European Medicines Agency and the United States Food and Drug Administration, has also boosted confidence among clinicians, leading to increased utilization rates

By Application Insights

The liquid form segment held a dominant share of the blood and blood components market in 2024. The overwhelming preference for liquid formulations stems from clinical necessity red blood cells, plasma, and platelets must be stored and administered in liquid or thawed liquid form to maintain biological activity and ensure patient safety. Refrigerated liquid red blood cells have a shelf life of up to 42 days under standard storage conditions, making them logistically viable for hospital blood banks. Liquid plasma, used in trauma resuscitation and massive transfusion protocols, is preferred in emergency departments for its immediate availability and compatibility with rapid infuser systems.

The lyophilized or freeze dried form of blood components segment is likely to grow with an anticipated CAGR of 12.3 % during the forecast period with the urgent need for deployable, ambient stable blood products in military, disaster relief, and remote clinical settings. Freeze dried plasma, already adopted by the United States Army and NATO forces, can be reconstituted in under six minutes and does not require refrigeration, making it ideal for battlefield trauma care. Startups like Hemanext and Velico Medical are pioneering next generation lyophilized platelet and hemoglobin based oxygen carriers, targeting regulatory approval by 2026.

By End-Users Insights

The hospitals segment was the largest and held a dominant share of the global blood and blood components market share in 2024 with the central role hospitals play in acute care, surgical interventions, oncology treatment, and emergency medicine all of which require substantial volumes of blood products. In Europe, the European Haematology Association estimates that surgical procedures alone consume over 45 % of all red cell units distributed. Hospitals also serve as the primary distribution point for specialized plasma derivatives such as Factor VIII and IX for hemophilia patients.

The academic and research institutions segment is likely to grow with an estimated CAGR of 10.9 % during the forecast period with the increased government and private funding for transfusion medicine, regenerative therapies, and artificial blood substitutes. In Asia, institutions like the National University of Singapore and Peking Union Medical College are investing in bioreactor technologies to scale up blood component synthesis.

REGIONAL ANALYSIS

North America Blood and Blood Components Market Analysis

North America blood and blood components market held 41.2% of the share in 2024. The United States is operating the world’s largest plasma collection infrastructure and consuming over 40 % of all plasma derived therapies globally. High healthcare expenditure is exceeding 4.3 trillion United States Dollars in 2023 according to the Centers for Medicare and Medicaid Services. Canada complements this ecosystem with its universal healthcare model by ensuring consistent demand across public hospitals.

Europe Blood and Blood Components Market Analysis

Europe blood and blood components market held 29.3% of share in 2024. Germany, France, and the United Kingdom are the dominant contributors, which is supported by well-established national blood services and universal healthcare coverage. The European Commission’s Horizon Europe program allocated 89 million Euros in 2023 to blood safety and supply chain resilience projects. Eastern European countries like Poland and Romania are emerging as key plasma collection markets due to favorable donor compensation laws and lower operational costs.

Asia Pacific Blood and Blood Components Market Analysis

Asia Pacific blood and blood components market is anticipated to grow with a significant CAGR during the forecast period. Japan maintains a technologically advanced transfusion system with 100% voluntary non remunerated donations, as confirmed by the Japanese Red Cross Society. Australia and South Korea are investing in automated blood processing and cold chain logistics to reduce wastage.

Latin America Blood and Blood Components Market Analysis

Latin America blood and blood components market is growing steadily in coming years. Brazil’s Unified Health System has invested in over 30 new regional blood centers since 2020 by improving rural access. Mexico’s National Blood Transfusion Center reported a 22 % increase in plasma collections in 2023 due to partnerships with private clinics. Private hospitals in Colombia and Peru are adopting automated transfusion systems, boosting demand for quality assured components.

Middle East and Africa Blood and Blood Components Market Analysis

The Middle East and Africa blood and blood components market growth is also to grow at slow growth in coming years. South Africa’s National Health Laboratory Service processed over 850 000 blood units in 2023, while Saudi Arabia’s Ministry of Health operates 17 automated blood banks serving its population of 36 million. Egypt launched a national digital donor registry in partnership with IBM, increasing donor retention by 30 % within six months. Conflict zones remain a challenge, but organizations like the International Committee of the Red Cross are deploying mobile blood collection units in Yemen and Sudan.

KEY MARKET PLAYERS

A few of the major companies in the global blood and blood components market include

• CSL Behring
• Grifols
• Octapharma
• Bio-Rad Laboratories
• Terumo Corporation
• Fresenius Kabi
• Haemonetics Corporation
• Becton
• Dickinson and Company (BD)
• Abbott Laboratories and Immucor

Top Players in the Market

Grifols is a global leader in plasma derived medicines and operates one of the largest plasma collection networks worldwide. The company collects plasma through hundreds of donation centers primarily in the United States and processes it into life-saving therapies for immune deficiencies and bleeding disorders. In 2023 Grifols expanded its manufacturing capacity in Spain and signed along term supply agreement with the United Kingdom National Health Service. The company also invested in next generation pathogen reduction technologies to enhance product safety and launched a digital donor engagement platform to increase plasma donation rates across North America.

CSL Behring specializes in high purity plasma and recombinant therapies used in hematology immunology and emergency care. The company operates advanced fractionation facilities in Australia Germany and the United States and maintains a robust clinical trial pipeline. In early 2024, CSL Behring received United States Food and Drug Administration approval for a novel recombinant Factor IX therapy with extended half-life. The company also partnered with academic institutions to develop gene therapies for rare bleeding disorders and enhanced its cold chain logistics to ensure global product availability even in remote regions.

Octapharma is a privately held biopharmaceutical company focused on human protein therapies derived from plasma and human cell lines. It serves patients in over 118 countries with products for hemophilia immune disorders and intensive care. The company also launched a global awareness campaign to promote voluntary blood donation and funded research into artificial platelet substitutes. Octapharma strengthened its regulatory footprint by securing approvals in Brazil India and South Korea for its next generation albumin and immunoglobulin products.

Top Strategies Used by Key Market Participants

Leading companies in the blood and blood components market focus on vertical integration to control plasma sourcing processing and distribution. They invest heavily in automation and digital platforms to optimize donor recruitment and inventory management. Strategic partnerships with hospitals and governments ensure long term supply contracts and policy influence. Research and development efforts target next generation therapies including recombinant proteins and gene editing solutions. Geographic expansion into emerging markets like India Brazil and Southeast Asia helps capture untapped demand. Companies also prioritize regulatory compliance and quality certifications to maintain global market access.

RECENT MARKET HAPPENINGS

In June 2023, in commemoration of World Blood Donor Day, the Pan American Health Organization (PAHO) calls for increased blood and plasma donations while highlighting its importance to ensure that countries maintain a safe and sustainable supply.\

MARKET SEGMENTATION

This research report on the global blood and blood components market has been segmented and sub-segmented based on product, application end-user, and region.

By Product

• Plasma Derived Products
• Platelets

By Application

• Liquid Form
• Lyophilized (Freeze-Dried) Form

By End-Users

• Hospitals
• Academic and Research Institutions

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa